HRMY · Company research
Harmony Biosciences Holdings, Inc. Common Stock (HRMY): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
28records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) stock price, news, quote and history - Yahoo Finance UK | Harmony Biosciences Holdings, Inc. (HRMY) stock price, news, quote and history Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 16, 2026 | neutral | 0 | 0.6 |
| HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? - Zacks Investment Research | HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? Zacks Investment Research | View source ↗ | Zacks Investment Research | Oct 16, 2026 | neutral | 0 | 0.6 |
| HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.333 | 1 |
| HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? | Harmony Biosciences (HRMY) has outperformed the market with a 27.6% share surge over six months, driven by robust Wakix sales growth of 24% to $476.7 million in H1 2026 and promising pipeline candidates BP-205 and EPX-100. The company maintains its $1.0-$1.04B full-year revenue guidance and has $962.5M in cash to fund development. However, competition from Jazz Pharmaceuticals' Xywav and Alkermes' Lumryz, along with patent litigation risks, present headwinds. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.333 | 1 |
| HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? - TradingView | HRMY Stock Gains 27.6% in Six Months: Is There More Room for Growth? TradingView | View source ↗ | TradingView | Oct 16, 2026 | neutral | 0 | 0.6 |
| Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance | Harmony Biosciences Holdings, I (HRMY) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - Stocktwits | HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? Stocktwits | View source ↗ | Stocktwits | Oct 14, 2026 | neutral | 0 | 0.6 |
| Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight | Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bullish | 1 | 1 |
| Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight | Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea. | View source ↗ | GlobeNewswire Inc. | Oct 13, 2026 | bullish | 1 | 1 |
| Why Harmony Biosciences Stock Got Mashed on Monday | Harmony Biosciences stock fell over 5% on Monday following the announcement of a planned CEO succession. Current COO Peter Anastasiou will replace CEO Jeffrey Dayno effective January 1, 2027, in a planned transition. Despite the company maintaining its strategic priorities and reiterating full-year Wakix revenue guidance of $1-$1.04 billion, investors reacted negatively to the leadership change. The analyst suggests this may present a buying opportunity at a discount. | View source ↗ | The Motley Fool | Oct 12, 2026 | bearish | -1 | 1 |
| Harmony Biosciences Announces Planned CEO Transition to Support Next Phase of Growth | Harmony Biosciences announced that Peter Anastasiou, current Sr. EVP and COO, will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno who will retire after nine years. The company reiterates its full-year 2026 WAKIX net revenue guidance of $1.0-1.04 billion and remains on track to report BP-205 MAD study data in Q4 2026. | View source ↗ | GlobeNewswire Inc. | Oct 12, 2026 | bullish | 1 | 1 |
| Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, News, Quote & History - Yahoo! Finance Canada | Harmony Biosciences Holdings, Inc. (HRMY) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Harmony Biosciences (HRMY) Short Interest & Short Float | Updated Oct 2026 - MarketBeat | Harmony Biosciences (HRMY) Short Interest & Short Float | Updated Oct 2026 MarketBeat | View source ↗ | MarketBeat | Oct 9, 2026 | neutral | 0 | 0.6 |
| Harmony Biosciences (HRMY) Heads To European Narcolepsy Days With New Phase 3 Data - Yahoo Finance | Harmony Biosciences (HRMY) Heads To European Narcolepsy Days With New Phase 3 Data Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Harmony Biosciences (HRMY) Stock Looks Below Fair Value As Shares Rose 48% - Yahoo Finance | Harmony Biosciences (HRMY) Stock Looks Below Fair Value As Shares Rose 48% Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance | Harmony Biosciences Holdings, I (HRMY) Stock Forecasts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 8, 2026 | neutral | 0 | 0.6 |
| HRMY vs. CSLLY: Which Stock Is the Better Value Option? | In a comparison of two medical-biomedical stocks, Harmony Biosciences Holdings (HRMY) emerges as the superior value option compared to CSL Limited Sponsored ADR (CSLLY). HRMY has a Zacks Rank of #2 (Buy) with improving earnings outlook, a forward P/E of 10.52, and a Value grade of A. CSLLY has a Zacks Rank of #4 (Sell) with a forward P/E of 19.66 and a Value grade of C, making it less attractive to value investors. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| HRMY vs. CSLLY: Which Stock Is the Better Value Option? | In a comparison of two medical-biomedical stocks, Harmony Biosciences Holdings (HRMY) emerges as the superior value option compared to CSL Limited Sponsored ADR (CSLLY). HRMY has a Zacks Rank of #2 (Buy) with improving earnings outlook, a forward P/E of 10.52, and a Value grade of A. CSLLY has a Zacks Rank of #4 (Sell) with a forward P/E of 19.66 and a Value grade of C, making it less attractive to value investors. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| HRMY vs. CSLLY: Which Stock Is the Better Value Option? - Yahoo Finance | HRMY vs. CSLLY: Which Stock Is the Better Value Option? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? | Harmony Biosciences (HRMY) is presented as an attractive value investment opportunity, holding a Zacks Rank #2 (Buy) rating and an A grade for Value. The stock trades at a P/B ratio of 2.42, P/S ratio of 2.42, and P/CF ratio of 9.34, all favorable compared to industry averages, suggesting the company may be undervalued in the market. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? | Harmony Biosciences (HRMY) is presented as an attractive value investment opportunity, holding a Zacks Rank #2 (Buy) rating and an A grade for Value. The stock trades at a P/B ratio of 2.42, P/S ratio of 2.42, and P/CF ratio of 9.34, all favorable compared to industry averages, suggesting the company may be undervalued in the market. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 1 | 1 |
| Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? - Yahoo Finance | Is Harmony Biosciences (HRMY) Stock Undervalued Right Now? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Harmony Biosciences Holdings Inc (MEX:HRMY) Stock Holders - Institutional & Insider Ownership - GuruFocus | Harmony Biosciences Holdings Inc (MEX:HRMY) Stock Holders - Institutional & Insider Ownership GuruFocus | View source ↗ | GuruFocus | Oct 5, 2026 | neutral | 0 | 0.6 |
| A drug being tested for two sleep disorders will be presented in Bern - Stock Titan | A drug being tested for two sleep disorders will be presented in Bern Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Harmony Biosciences (HRMY) Stock Looks Below Fair Value On Earnings - Simply Wall Street | Harmony Biosciences (HRMY) Stock Looks Below Fair Value On Earnings Simply Wall Street | View source ↗ | Simply Wall Street | Aug 1, 2026 | neutral | 0 | 0.6 |
| Should Value Investors Buy Harmony Biosciences (HRMY) Stock? - Yahoo Finance | Should Value Investors Buy Harmony Biosciences (HRMY) Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 30, 2026 | neutral | 0 | 0.6 |
| HRMY vs. AMGN: Which Stock Is the Better Value Option? - Yahoo Finance | HRMY vs. AMGN: Which Stock Is the Better Value Option? Yahoo Finance | View source ↗ | Yahoo Finance | Jul 14, 2026 | neutral | 0 | 0.6 |
| Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? - Yahoo Finance | Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? Yahoo Finance | View source ↗ | Yahoo Finance | Jun 29, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.